Pharmaceutical development of tablets based on cryolyophilized porcine skin

Abstract

Among natural sources of animal origin, the most similar to human in composition is porcine skin. Crushed cryolyophilized xenoderm of porcine skin from 1st layer is used for preparation a dietary supplement Xenoderm in the form of powder, capsules and tablets. Also, an additional natural active pharmaceutical ingredient is 2nd layer from cryolyophilized xenoderm of porcine skin, which was not used before. In this study, composition and technology of combined tablets based on the powders of the 1st and 2nd layers from the cryolyophilized xenoderm of porcine skin were develop and characterized. It was evaluated pharmaco-technological properties of the tableting blend such as bulk density, tapped density, flowability and angle of repose. The tablets were prepared by direct compression method. They were studied for appearance, uniformity of dosage units, hardness, friability and disintegration. The effect of fillers, disintegrants, and glidants on 9 pharmaco-technological properties of the tableting blend and tablets was investigated using dispersion analysis. By desirability function the advantages of Neusilin® US2, calcium dihydrogen phosphate anhydrous and sorbitol, croscarmellose sodium and polyplasdone XL-10 are shown. The quantities of excipients were investigated using method of random balance. The interaction between quantities of excipients and the quality of tableting blend and tablets was proved using method of regression analysis. Optimal combination of croscarmellose sodium, Neusilin® US2, microcrystalline cellulose 102 and magnesium stearate is justified. New combined tablets under the conventional name Combiderm are obtained by direct compression method. Optimal tablet pressing parameters are selected in the range from 290 MPa to 435 MPa. We successfully prepared the tablets with a good consumer appearance and conformity pharmacopoeial requirements. The proposed methodology could be an algorithm for the pharmaceutical development of other combined tablets using statistical methods.

Keywords

Pharmaceutical development of tablets / Cryolyophilized porcine skin / Dispersion analysis / Method of random balance / Regression analysis / Tablet pressing parameters

Ethics approval

Not applicable.

Declaration of generative AI in scientific writing

No generative AI tools have been used throughout the entire writing process of this manuscript.

Funding information

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability

There is the supplementary material to this article.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The author would like to express great appreciation to Institute of Biomedical Technologies LCC (Ternopil, Ukraine) for providing raw materials.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.pscia.2025.100082.2.

References

[1] B. Vons, O. Tryhubchak, T. Groshovuy, M. Chubka, V. Bihunyak, Research of powders of the cryolyophilized xenoderm of porcine skin, Int. J. Green Pharm. 12 (3) (2018) S657-S664, https://doi.org/10.22377/ijgp.v12i03.2035.

[2] A.V. Tsymbaliuk, Antitoxic phenomenon of crylufilized xenodermal substrate, Med. Chem. 14 (2) (2013) 99-103, https://doi.org/10.11603/1681-2557.2012.v14.i2.706.

[3] LLC Institute of biomedical technologies, Lyophilized xenoderm grafts. Institute of biomedical technologies. https://ibt.in.ua/eng/ksenoderm.html. (Accessed 26 January 2025).

[4] N.V. Pasechnikova, S.A. Yakimenko, N.V. Turchin, A.I. Buznik, P.A. Kostenko, The use of "keratoxenoimplant" for therapeutic and therapeutic-tectonic keratoplasty in severe eye burns and corneal ulceration of various etiologies, Ophthalmol. J. 5 (466) (2015) 13-17. http://www.ozhurnal.com/sites/default/files/2015-5-3ru.pdf.

[5] Z.L. Savchuk, I.M. Klishch, Application of keratoxenoimplant in the cases of experimental chemical burn of the cornea associated with hypothyroidism, Med. Clin. Chem. 17 (3) (2015) 10-15, https://doi.org/10.11603/mcch.2410681X.2015.v17.i3.5043.

[6] L.N. Skakun, A.V. Cimbaluk, The experience with the application of a lyophilized xenodermograft for the treatment of the patients suffering from frequently recurring inflammation of the maxillary sinus in combination with alveolar fistula, Vestn. Otorinolaringol. 80 (3) (2015) 45-46, https://doi.org/10.17116/otorino201580345-46.

[7] L.M. Skakun, Improving of the method of odontogenic maxillary sinusitis treatment, Clin. Dent. 1 (2015) 95-98. https://ojs.tdmu.edu.ua/index.php/kl-stomat/article/download/6175/5652.

[8] G.I. Borshevskiy, Theoretical Substantiation and Development of Liposomal Drugs in the Form of Solution for Injections and Spray Based on Nanobiotechnology, Dissertation, National pharmaceutical university, 2016, http://dspace.nuph.edu.ua/handle/123456789/10093.

[9] V.V. Bihuniak, V.V. Demianenko, Piatnytskyi YuS, P.A. Denyschuk, Bioadsorbent. UA patent 36775, 08 May 2008. https://base.uipv.org/searchINV/search.php?action=viewdetails&IdClaim=125612&chapter=biblio.

[10] A.V. Tsymbalyuk, Pathogenetic Features of the Course of Burn Disease Under the Conditions of Its Experimental Therapy with a Crushed Substrate of Cryolyophilized Xenoskin, Dissertation, I.Ya. Horbachevsky Ternopil State Medical University, 2013, http://www.disslib.org/patohenetychni-osoblyvosti-perebihu-opikovoyi-khvoroby-za-umov-yiyi-eksperymentalnoyi.html.

[11] Yu. S. Pyatnytsky, Yu. I. Bondarenko, O. V. Denefil, The effect of the grinded substrate of the preserved pig skin on the manifestations of experimental allergic dermatitis, Herald Prob. Biol. Med. 3 (2) (2014) 225-229. http://nbuv.gov.ua/UJRN/Vpbm_2014_3%282%29_46.

[12] Yu. S Pyatnytsky, I. M. Klishch, Research of the efficiency of milled substrate of canned pig skn at the experimental atopic dermatitis, Hospital Surg. 4 (2014) 63-66, https://doi.org/10.11603/1681-2778.2014.68.4384.

[13] Yu. S. Pyatnitsky, Yu. I. Bondarenko, N. Ya. Potikha, Investigation of gonadotoxicity and embryotoxicity action of granulated substrate of preserved pig skin, Clin. Exp. Pathol. 13 (2) (2014) 108-113, 48, http://irbis-nbuv.gov.ua/cgi-bin/irbis_nbuv/cgiirbis_64.exe?C21COM=2&I21DBN=UJRN&P21DBN=UJRN&IMAGE_FILE_DOWNLOAD=1&Image_file_name=PDF/kep_2014_13_2_28.pdf.

[14] V.B. Hoshchyns'kyy, T.Ya. Boyko, Method of experimental therapy of gastric ulcer, UA Patent 27174 (26 Apr 2007). https://base.uipv.org/searchINV/search.php?action=viewdetails&IdClaim=99488&chapter=biblio.

[15] Yu. A. Ravliv, Development of Technology and Research of Medicinal Products Based on Cryolyophilized Xenoderm, Dissertation, Danylo Halytsky Lviv National Medical University, 2015, http://www.disslib.org/rozrobka-tekhnolohiyi-ta-doslidzhennja-likarskykh-zasobiv-na-osnovi.html.

[16] T.A. Hroshovyy, V.V. Dem'yanenko, A.V. Tsymbalyuk, Yu.A. Ravliv, Tableted product based on cryolyophilized pig skin, UA Patent 102645 (26 Jun 2012). https://base.uipv.org/searchINV/search.php?action=viewdetails&IdClaim=189513.

[17] T.A. Hroshovyy, V.V. Dem'yanenko, A.V. Tsymbalyuk, Yu.A. Ravliv, A tablet containing active compounds of bio-organic origin, UA Patent 74077 (25 May 2012). https://base.uipv.org/searchINV/search.php?action=viewdetails&IdClaim=189513.

[18] T.A. Hroshovyy, Yu.A. Ravliv, O.V. Tryhubchak, A.V. Tsymbalyuk, Tableted product based on cryolyophilized pig skin with lecithin, UA Patent 90662 (27 Nov 2013). https://base.uipv.org/searchINV/search.php?action=viewdetails&IdClaim=201259.

[19] LLC Institute of biomedical technologies, Dietary supplement "Xenoderm". Institute of biomedical technologies. https://ibt.in.ua/eng/ksenoderm.html. (Accessed 26 January 2025).

[20] V.V. Bihunyak, A.O. Koval'chuk, T.V. Romanyuk, Biodegrading properties of the xenoderm-graft of the secondary section in plastic surgery of weakly granulating wounds, Bullet. Scientific Res. 1 (2012) 56-57. https://scholar.google.com.ua/citations?view_op=view_citation&hl=uk&user=CgZ_720AAAAJ&citation_for_view=CgZ_720AAAAJ:WF5omc3nYNoC.

[21] N.V. Huda, V.V. Bihunyak, H.V. Bihunyak, The method of making xenodermal grafts. UA patent 88344. https://base.uipv.org/searchINV/search.php?action=viewdetails&IdClaim=137044, 23 Jul 2007.

[22] O.V. Tryhubchak, T.A. Hroshovyy, V.V. Bihunyak, Choice of optimal conditions for grinding cryo-lyophilized pig xenoderma, Bullet. Pharm. Vitebsk State Med. Univ. 4 (70) (2015) 44-50. https://www.academia.edu/30028395/Ве%D1%81%D1%82%D0%BD%D0%B8%D0%BA_%D1%84%D0%B0%D1%80%D0%BC%D0%B0%D1%86%D0%B8%D0%B8_2015_%D0%B3%D0%BE%D0%B4_%D0%BD%D0%BE%D0%BC%D0%B5%D1%804_pdf.

[23] T.A. Hroshovyy, V.P. Martsenyuk, L.I. Kucherenko, L.V. Vronska, S.N. Gureeva, Mathematical planning of an experiment during scientific research in pharmacy, Ukrmedknyga, Ternopil (2008). https://scholar.google.com/citations?view_op=view_citation&hl=th&user=mOnS1B0AAAAJ&citation_for_view=mOnS1B0AAAAJ:BrmTIyaxlBUC.

[24] European Directorate for the Quality of Medicines & HealthCare, European Pharmacopoeia, eleventh ed., Council of Europe, Strasbourg Cedex, 2023.

[25] O.V. Tryhubchak, T.A. Hroshovyy, V.V. Bihunyak, Tablets of cryolyophilized pig xenoderm, UA Patent118944 (02 Jul, https://base.uipv.org/searchINV/search.php?action=viewdetails&IdClaim=256721, 2018.